Oct 03, 2019 - Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Oct 03, 2019 - Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
Oct 02, 2019 - Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.
Sep 30, 2019 - Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Sep 26, 2019 - GLP-1 drugs keep getting easier to take.
Sep 26, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Sep 26, 2019 - Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
Sep 24, 2019 - The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.
Sep 23, 2019 - AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.